Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
3.656
-0.044 (-1.18%)
Sep 4, 2026, 9:57 AM EDT - Market open

Liminatus Pharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-4.07-2.97-3.33-4.82-2.71-4
Net Income
-12.52-10.21-3.55-4.98-2.93-5.61
Earnings Per Share
-18.06-21.48-10.13-2.43-4.12-
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3.020.340.060.435.050
Total Debt
1.441.4419.9716.0516.513.18
Net Cash (Debt)
1.57-1.1-19.92-15.62-11.45-13.18
Net Cash Growth
------
Net Cash Per Share
2.27-2.33-56.90-7.62-16.10-

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-3.97-9.96-1.45-3.35-0.87-0.17
Capital Expenditures
-0.01-0.01----
Free Cash Flow
-3.99-9.98-1.45-3.35-0.87-0.17
Free Cash Flow Growth
------